黄玉辉
教授，博士生导师
江苏省苏州市工业园区仁爱路199号703号楼507室
www.优德88.cpm 唐仲英血液学研究中心
电话：86-512-65880877-3507
传真：86-512-65880929
Email:huangyh@suda.edu.cn
教育背景：
1992年-1996年：南京大学，生物化学系，学士
2000年-2003年：中科院上海生命www.优德88.cpm 院，分子生物学与生物化学专业，硕士
2003年-2007年：美国Vanderbilt University，肿瘤生物学专业，博士
2008年-2013年:美国哈佛大学医学院麻省总医院，博士后
工作经历：
1996年7月-2000年8月：丽珠医药集团股份有限公司，工程师
2014年1月-2014年6月：美国Mayo Clinic，助理教授
2014年7月-至今：www.优德88.cpm，特聘教授
研究领域及内容：肿瘤免疫微环境和免疫治疗
肿瘤在我国的发生率和死亡率正逐年上升，而传统的化疗和放疗往往仅能短暂延长病人的寿命。近年来在肿瘤免疫治疗上的进展为治愈恶性肿瘤带来了一丝曙光。目前，肿瘤免疫治疗面临的一大障碍是异常的肿瘤血管和免疫抑制性的肿瘤微环境。它们不仅阻碍抗肿瘤有效成分的输送，而且也抑制了它们的活性和导致了抗药性。我的实验室将致力于研究肿瘤免疫微环境的特性及形成机理，解析肿瘤血管与免疫系统之间的交互作用机制，并通过融合肿瘤免疫学、肿瘤血管控制、生物靶标、影像学和数学模型等来发展高效特异的肿瘤精准免疫治疗策略。
团队成员：
研究助理/副教授：招聘中
博士研究生：郑曦晨、刘永浩、范鹏、戚子蔚、张耐冬、马珂、冒训圆、高海婷
硕士研究生：房兆续、文成文、周培、刘小梅、邓声明、钱龙、蒯佳婕、何燕、郭书欣、黄梦梦、王均晖、孙连塞、汪莹、刘延坤、高梦、王珊珊
代表性成果：
1.Zhang N#, Yin R#, Zhou P#, Liu X#, Fan P, Qian L, Dong L, Zhang C, Zheng X, Deng S, Kuai J, Liu Z, Jiang W, Wang X*, Wu D*,Huang Y*. DLL1 orchestrates CD8+T cells to induce long-term vascular normalization and tumor regression.Proc. Natl. Acad. Sci. U S A, 118 (22): e2020057118, 2021.
2.Zheng X#, Fang Z#, Liu X, Zhou P, Deng S, Wang X, Zhang C, Yin R, Hu H, Chen X, Zhao Y, Lin S, Qin S, Wang X, Kim B, Zhou P, Jiang W, Wu Q,Huang Y*. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.J. Clin. Invest.128(5): 2104-2115, 2018.
3.Huang Y*, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W*. Improving immune-vascular crosstalk for cancer immunotherapy.Nat. Rev. Immunol.18(3): 195-203, 2018.
4.Zheng X, Zhang N, Qian L, Wang X, Fan P, Kuai J, Lin S, Liu C, Jiang W, Qin S, Chen H* andHuang Y*, CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils,Int. J. Cancer, 146(6):1730-1740, 2020.
5.Liu Y#, Song Y#, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, Zhao L, Teo KY, Qiu J, Jiang W, Dong C, Wu D*,Huang Y*, Liu H*. NCR group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development.EBioMedicine, 41:333-344, 2019.
6.Deng S#, Zhang G#, Kuai J, Fan P, Wang X, Zhou P, Yang D, Zheng X, Liu X, Wu Q*,Huang Y*. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner.J. Exp. Clin. Cancer Res.37(1): 260, 2018.
7.Peterson TE#, Kirkpatrick ND#,Huang Y#, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D*, Jain RK*. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Proc. Natl. Acad. Sci. U S A113(16): 4470-5, 2016.
8.Jiang W#,Huang Y#, An Y, Kim B*. Remodelling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles.ACS Nano.9(9): 8689-96, 2015.
9.Huang Y, Carbone DP*. Mechanisms of and Strategies for Overcoming Resistance to Anti-vascular Endothelial Growth Factor Therapy in Non-small Cell Lung Cancer.BBA Reviews on Cancer1855(2):193-201, 2015.
10.Huang Y, Goel S, Duda DG, Fukumura D, Jain RK*. Vascular normalization as an emerging strategy to enhance cancer immunotherapy.Cancer Res.73: 2943-8, 2013.
11.Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK*. Benefits of vascular normalization are dose and time dependent-letter.Cancer Res.73: 7144-6, 2013.
12.Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK*, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.Proc. Natl. Acad. Sci. U S A109: 17561-6, 2012.
13.Huang Y, Snuderl M, Jain RK*. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity.Cancer Cell19: 1-2, 2011.
14.Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP*. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth.Cancer Res.71: 6122-31, 2011.
15.Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP*. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.Blood110: 624-31, 2007.
16.Snuderl M#, Batista A#, Kirkpatrick ND#, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R,Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK*. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.Cell152: 1065-76, 2013.
17.Incio J, Ligibel JA, McManus DT, Suboj P, Pinter M, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD,Huang Y, Rahbari N, Roberge S, Wang D, Gomes-Santos I, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda D, Boucher Y, Fukumura D*, Jain RK*. Obesity promotes resistance to anti-VEGF therapy in breast cancer by upregulating IL-6 and FGF-2,Sci. Transl. Med.10(432): eaag0945, 2018.
18. Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S,Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D*, Jain RK*.Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy.Cancer Discov.6(8): 852-869, 2016.
荣誉称号:
2019国家科学技术进步奖（二等奖）
2019www.优德88.cpm 周氏教育科研奖
2015江苏省“双创团队”
2015江苏省“六大高峰人才”
2014江苏省第五批“特聘教授”
2014Distinguished Oral Presentation in Mayo Clinic Young Investigator Research Symposium
2010AACR-Aflac Scholar-in-Training Award
2007AACR-Merck Scholar-in-Training Award